PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
R&D reduction while AGEN shows 16.77% growth. Joel Greenblatt would examine competitive risk.
44.07%
G&A growth above 1.5x AGEN's 13.25%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
6.92%
Operating expenses growth 50-75% of AGEN's 13.25%. Bruce Berkowitz would examine efficiency.
6.92%
Total costs growth less than half of AGEN's 14.88%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A growth above 1.5x AGEN's 21.14%. Michael Burry would check for excessive investment.
73.55%
EBITDA growth exceeding 1.5x AGEN's 8.05%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Operating income decline while AGEN shows 16.33% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
121.05%
Pre-tax income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS growth while AGEN declines. John Neff would investigate advantages.
115.11%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
2.25%
Share count reduction exceeding 1.5x AGEN's 23.84%. David Dodd would verify capital allocation.
42.15%
Diluted share reduction below 50% of AGEN's 23.84%. Michael Burry would check for concerns.